Core Scientific Stock Upgraded as Standalone Prospects Outweigh Acquisition Hopes
Investment firm Roth Capital Partners has upgraded Core Scientific to buy despite fading acquisition prospects. Analysts suggest the company’s standalone value lies in leasing its substantial power capacity for high-performance computing applications.
Analyst Upgrade Amid Shifting Acquisition Landscape
Roth Capital Partners has reportedly upgraded Core Scientific shares from neutral to buy, according to recent analyst reports, even as the potential acquisition by CoreWeave appears less likely. Analyst Darren Aftahi simultaneously raised his 12-month price target to $23.50 from $17, suggesting a potential 32% gain based on the company’s standalone prospects.